Assessment of castrate testosterone levels in patients with advanced prostate cancer

QIU Zhi,SUN Yu-cheng,SHAO Qiang,ZHANG Yi,DU Lin-dong,邱智,孙玉成,邵强,张弋,杜林栋
DOI: https://doi.org/10.3760/j:issn:1000-6702.2006.02.015
2006-01-01
Abstract:Objective To determine the average of the castrate testosterone level in patients with advanced prostate cancer,and to provide endocrine therapy implication. Methods A total of 40 consecutive advanced prostate cancer patients not treated with any anti-androgen medications 12 months after castration were enrolled.Serum levels of testosterone and prostatic specific antigen (PSA) were obtained just prior to castration,and 1 week and 1,3,6,9,12 months after castration. Results ①No significant change of testosterone level was found in these patients within 6 post-castration months.The average of castrate testosterone level was <1.9 nmol/L (95% confidence interval,1.2-1.9 nmol/L).The castrate level in 32.5%(13/40) of the patients,whose average Gleason score was 6.8, had the average castrate level >1.9 nmol/L.②At 6 months after castration,PSA<1 ng/ml was found in 36 patients with average Gleason score 6.3; the other 4 patients with PSA >1ng/ml had average Gleason score 8.0. Conclusions The average testosterone level is less than 1.9 nmol/L after bilateral orchiectomy.Patients whose testosterone does not reach this level require further anti-androgen therapy.After castration,PSA level decreases progressively, and reaches the bottom around 6 months.
What problem does this paper attempt to address?